Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Bristol Myers Squibb (NYSE: BMY) has announced its participation in two upcoming investor conferences in September 2024. Christopher Boerner, Board Chair and CEO, and David Elkins, EVP and CFO, will engage in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5 at 1:05 p.m. ET. Adam Lenkowsky, EVP and Chief Commercialization Officer, will participate in a similar session at the 2024 Wells Fargo Healthcare Conference on September 6 at 9:30 a.m. ET.
Both sessions will be accessible to investors and the public via http://investor.bms.com. Archived versions will be available after the events conclude. These conferences provide an opportunity for BMY to address questions about the company and engage with the investment community.
Bristol Myers Squibb (NYSE: BMY) ha annunciato la sua partecipazione a due conferenze per investitori previste per settembre 2024. Christopher Boerner, Presidente del Consiglio e CEO, e David Elkins, EVP e CFO, parteciperanno a una chiacchierata informale durante il 22° Convegno Annuale globale sulla salute di Morgan Stanley il 5 settembre alle 13:05 ET. Adam Lenkowsky, EVP e Direttore Commerciale, parteciperà a una sessione simile al 2024 Wells Fargo Healthcare Conference il 6 settembre alle 9:30 ET.
Entrambe le sessioni saranno accessibili agli investitori e al pubblico tramite http://investor.bms.com. Le versioni archiviate saranno disponibili dopo il termine degli eventi. Queste conferenze offrono a BMY l'opportunità di rispondere alle domande sulla società e interagire con la comunità degli investitori.
Bristol Myers Squibb (NYSE: BMY) ha anunciado su participación en dos conferencias para inversores que se llevarán a cabo en septiembre de 2024. Christopher Boerner, Presidente de la Junta y CEO, y David Elkins, EVP y CFO, participarán en una charla informal en la 22ª Conferencia Global Anual de Atención Médica de Morgan Stanley el 5 de septiembre a la 1:05 p.m. ET. Adam Lenkowsky, EVP y Director de Comercialización, participará en una sesión similar en la Conferencia de Atención Médica Wells Fargo 2024 el 6 de septiembre a las 9:30 a.m. ET.
Ambas sesiones estarán disponibles para inversores y el público a través de http://investor.bms.com. Las versiones archivadas estarán disponibles después de que finalicen los eventos. Estas conferencias ofrecen a BMY la oportunidad de abordar preguntas sobre la empresa e interactuar con la comunidad inversora.
Bristol Myers Squibb (NYSE: BMY)는 2024년 9월에 예정된 두 개의 투자자 회의에 참여할 것이라고 발표했습니다. Christopher Boerner, 이사회 의장 및 CEO, 그리고 David Elkins, EVP 및 CFO는 9월 5일 오후 1:05 ET에 모건 스탠리 제22회 연례 글로벌 헬스케어 회의에서 대화 형식의 세션에 참석할 것입니다. Adam Lenkowsky, EVP 및 상업화 책임자도 9월 6일 오전 9:30 ET에 2024 웰스 파고 헬스케어 회의에서 비슷한 세션에 참석할 예정입니다.
두 세션 모두 투자자와 일반 대중이 http://investor.bms.com를 통해 접근할 수 있습니다. 이벤트 종료 후 아카이브 버전이 제공될 것입니다. 이러한 회의는 BMY가 회사에 대한 질문에 답하고 투자자 커뮤니티와 교류할 수 있는 기회를 제공합니다.
Bristol Myers Squibb (NYSE: BMY) a annoncé sa participation à deux conférences pour investisseurs prévues en septembre 2024. Christopher Boerner, Président du Conseil et CEO, ainsi que David Elkins, EVP et CFO, participeront à une discussion informelle lors de la 22e Conférence mondiale annuelle sur la santé de Morgan Stanley le 5 septembre à 13h05 ET. Adam Lenkowsky, EVP et Responsable de la commercialisation, participera à une session similaire lors de la Conférence sur la santé Wells Fargo 2024 le 6 septembre à 9h30 ET.
Les deux sessions seront accessibles aux investisseurs et au public via http://investor.bms.com. Des versions archivées seront disponibles après la conclusion des événements. Ces conférences offrent à BMY l'opportunité de répondre aux questions sur l'entreprise et d'interagir avec la communauté des investisseurs.
Bristol Myers Squibb (NYSE: BMY) hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 bekannt gegeben. Christopher Boerner, Vorsitzender des Vorstands und CEO, sowie David Elkins, EVP und CFO, werden am 5. September um 13:05 Uhr ET an einem Gespräch im 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley teilnehmen. Adam Lenkowsky, EVP und Chief Commercialization Officer, wird an einer ähnlichen Sitzung auf der 2024 Wells Fargo Healthcare Conference am 6. September um 9:30 Uhr ET teilnehmen.
Beide Sitzungen werden für Investoren und die Öffentlichkeit über http://investor.bms.com zugänglich sein. Archivierte Versionen werden nach dem Ende der Veranstaltungen verfügbar sein. Diese Konferenzen bieten BMY die Möglichkeit, Fragen zum Unternehmen zu beantworten und mit der Investmentgemeinschaft in Kontakt zu treten.
- None.
- None.
Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer, and David Elkins, Executive Vice President, Chief Financial Officer, will take part in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024. They will answer questions about the company beginning at 1:05 p.m. ET.
Adam Lenkowsky, Executive Vice President, Chief Commercialization Officer, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on September 6, 2024. He will answer questions about the company beginning at 9:30 a.m. ET.
Investors and the general public are invited to listen to both sessions at their respective times by visiting http://investor.bms.com. An archived edition of each session will be available following its conclusion.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X (formerly Twitter), YouTube, Facebook, and Instagram.
corporatefinancial-news
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827567364/en/
Media:
media@bms.com
Investors:
investor.relations@bms.com
Source: Bristol Myers Squibb
FAQ
When will Bristol Myers Squibb (BMY) participate in the Morgan Stanley Global Healthcare Conference?
Who will represent BMY at the 2024 Wells Fargo Healthcare Conference?
How can investors listen to BMY's presentations at the upcoming conferences?
Will archived versions of BMY's conference sessions be available?
